The inhibitory effect of curzerene on cell proliferation was reversed upon treatment with an mTOR agonist, indicating that curzerene's ability to inhibit glioma proliferation depends on the downregulation of the mTOR/p70S6K axis. Here, RPS6KB1 is linked to central nervous system cancer.